Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=1098
50 to 70% patients with GERD and 49% patients with heartburn tend to have nonerosive reflux disease, hence increasing prevalence of GERD and heartburn attributing to growth of nonerosive reflux disease treatment market. Development of GERD, Heartburn and nonerosive reflux disease is correlating to increasing prevalence of obesity and other dietary factors which are driving nonerosive reflux disease treatment market. Consequential impact on health related quality of life along with work related productivity is indicative of more chances to develop NERD which in term driving nonerosive reflux disease treatment market. Various studies have concluded that patients with nonerosive reflux disease have 20 to 30% less chances of getting relief from acid-blocking drugs hence making it difficult to treat nonerosive reflux disease with PPI. Non-availability of efficient treatment acting as a restraint in nonerosive reflux disease treatment market growth. Difficulty in diagnosis of nonerosive reflux disease further makes treatment difficult attributing to low nonerosive reflux disease market growth. Higher doses of proton pump inhibitor drugs are reported to develop adverse events further making nonerosive reflux disease treatment difficult. There is no treatment strategy established for nonerosive reflux disease treatment.
The global nonerosive reflux disease treatment market is classified on the basis of product type, distribution channel and region
Based on the drug type nonerosive reflux disease treatment market is segmented into following:
- Proton pump inhibitors
- H2 – blockers
Based on the distribution channel nonerosive reflux disease treatment market is segmented into following:
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
On the basis of geography, global nonerosive reflux disease treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Region wise North America is most lucrative market due increased prevalence of gastroesophageal reflux disease (GERD) and heartburn. Health related lifestyle correlating to obesity in North America is responsible for increasing nonerosive reflux disease treatment market and is only expected to grow. Nonerosive reflux disease is most common in patients with GERD and prevalence of gastroesophageal reflux disease (GERD) in North America (20%), Europe (9-17%) Asia Pacific (2-5%) once a week which is further responsible for nonerosive reflux disease treatment.
Various studies are going to develop strategy for treatment and diagnosis enhancing growth on nonerosive reflux disease market. Many studies are going on to distinguish nonerosive reflux disease patients from those with erosive esophagitis to make diagnosis and nonerosive reflux disease treatment efficient. Rising clinical studies in nonerosive reflux disease treatment are expected to drive market growth over forecast period. Advanced drug molecule development in proton pump inhibitor class is expected to improve PPI result in nonerosive reflux disease treatment. By drug type proton pump inhibitors segment is most preferred for nonerosive reflux disease treatment. By distribution channel retail pharmacies segment is expected to dominate due high preference. Increased studies to evaluate nonerosive reflux disease diagnosis and treatment is further attributed to drive nonerosive reflux disease treatment market.
To know more about the Nonerosive Reflux Disease Treatment, Visit the link- https://www.factmr.com/report/1098/nonerosive-reflux-disease-treatment-market
Key major players in the nonerosive reflux disease treatment market are: AstraZeneca plc, Eisai Co, GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd, Johnson & Johnson, Daewoong Pharmaceutical Co., Ltd.; Ironwood Pharmaceuticals, Inc.; SRS Pharmaceuticals Pvt. Ltd.; and SFJ Pharmaceuticals Group
The report covers exhaustive analysis on:
- Nonerosive reflux disease treatment Market Segments
- Nonerosive reflux disease treatment Market Dynamics
- Historical Actual Market Size, 2013 - 2017
- Nonerosive reflux disease treatment Market Size & Forecast 2018 to 2024
- Nonerosive reflux disease treatment Agents Current Trends/Issues/Challenges
- Competition & Companies involved
- Nonerosive reflux disease treatment Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=1098
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852
Read Industry News at - https://www.industrynewsanalysis.com/